Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action blockers |
Mechanism KCNN4 blockers(Intermediate conductance calcium-activated potassium channel protein 4 blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | United States | 06 Dec 2017 | |
| Autoimmune Diseases | Preclinical | Netherlands | 06 Dec 2017 | |
| Autoinflammatory disease | Preclinical | United States | 06 Dec 2017 | |
| Autoinflammatory disease | Preclinical | Netherlands | 06 Dec 2017 |






